These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15943892)

  • 21. Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
    Han SW; Kim TY; Lee KH; Hwang PG; Jeon YK; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ
    Lung Cancer; 2006 Nov; 54(2):201-7. PubMed ID: 16956694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
    Rosell R; Viteri S; Molina MA; Benlloch S; Taron M
    Curr Opin Oncol; 2010 Mar; 22(2):112-20. PubMed ID: 19949333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
    Qiao J; Chen W
    Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111
    [No Abstract]   [Full Text] [Related]  

  • 24. [Molecular diagnostics in lung carcinoma for therapy stratification].
    Heukamp LC; Büttner R
    Pathologe; 2010 Feb; 31(1):22-8. PubMed ID: 19997736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
    Woo HS; Ahn HK; Lee HY; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Invest New Drugs; 2014 Dec; 32(6):1311-5. PubMed ID: 25146938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
    Oda N; Hotta K; Yoshioka H; Kudo K; Ichihara E; Kato Y; Ninomiya K; Minami D; Ninomiya T; Kubo T; Ohashi K; Sato A; Takigawa N; Tabata M; Tanimoto M; Kiura K
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):941-947. PubMed ID: 27590708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
    Inoue A; Yoshida K; Morita S; Imamura F; Seto T; Okamoto I; Nakagawa K; Yamamoto N; Muto S; Fukuoka M
    Jpn J Clin Oncol; 2016 May; 46(5):462-7. PubMed ID: 26977054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
    Sone T; Kasahara K; Kimura H; Nishio K; Mizuguchi M; Nakatsumi Y; Shibata K; Waseda Y; Fujimura M; Nakao S
    Cancer; 2007 May; 109(9):1836-44. PubMed ID: 17387741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 32. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR mutation and response of lung cancer to gefitinib.
    Toyooka S; Kiura K; Mitsudomi T
    N Engl J Med; 2005 May; 352(20):2136; author reply 2136. PubMed ID: 15901872
    [No Abstract]   [Full Text] [Related]  

  • 34. ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
    Wang Z; Li Z; Ding X; Shen Z; Liu Z; An T; Duan J; Zhong J; Wu M; Zhao J; Zhuo M; Wang Y; Wang S; Sun Y; Bai H; Wang J
    Sci Rep; 2015 Jun; 5():11392. PubMed ID: 26096604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    Chic N; Mayo-de-Las-Casas C; Reguart N
    J Thorac Oncol; 2017 Jun; 12(6):e78-e80. PubMed ID: 28532569
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
    Chang AY
    Expert Opin Investig Drugs; 2008 Mar; 17(3):401-11. PubMed ID: 18321238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 38. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
    Biaoxue R; Shuanying Y; Wei L; Wei Z; Zongjuan M
    Curr Med Res Opin; 2012 Oct; 28(10):1699-708. PubMed ID: 22978775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
    Doss GP; Rajith B; Chakraborty C; NagaSundaram N; Ali SK; Zhu H
    Sci Rep; 2014 Aug; 4():5868. PubMed ID: 25091415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.